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Abstract
DNA topoisomerase I (Top1) is over-expressed in tumour cells and is an important target in cancer chemotherapy. It relaxes
DNA torsional strain generated during DNA processing by introducing transient single-strand breaks and allowing the
broken strand to rotate around the intermediate Top1 – DNA covalent complex. This complex can be trapped by a group of
anticancer agents interacting with the DNA bases and the enzyme at the cleavage site, preventing further topoisomerase
activity. Here we have identified novel Top1 inhibitors as potential anticancer agents by using a combination of structure-
and ligand-based molecular modelling methods. Pharmacophore models have been developed based on the molecular
characteristics of derivatives of the alkaloid camptothecin (CPT), which represent potent antitumour agents and the main
group of Top1 inhibitors. The models generated were used for in silico screening of the National Cancer Institute (NCI, USA)
compound database, leading to the identification of a set of structurally diverse molecules. The strategy is validated by the
observation that amongst these molecules are several known Top1 inhibitors and agents cytotoxic against human tumour
cell lines. The potential of the untested hits to inhibit Top1 activity was further evaluated by docking into the binding site of
a Top1 – DNA complex, resulting in a selection of 10 compounds for biological testing. Limited by the compound
availability, 7 compounds have been tested in vitro for their Top1 inhibitory activity, 5 of which display mild to moderate
Top1 inhibition. A further compound, found by similarity search to the active compounds, also shows mild activity.
Although the tested compounds display only low in vitro antitumour activity, our approach has been successful in the
identification of structurally novel Top1 inhibitors worthy of further investigation as potential anticancer agents.
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Introduction
DNA topoisomerases relax DNA torsional strain generated
during replication, transcription, recombination, repair, and
chromosome condensation [1], and are therefore vital to all cells
undergoing division. The relaxation of DNA supercoiling by
topoisomerase I (Top1) is enabled by a mechanism of controlled
rotation around a transient DNA single-strand break [2,3]. During
this process, the enzyme forms an intermediate covalent complex
with the DNA, mediated by a bond between the active site tyrosine
(Tyr723 in human Top1) and the cleaved phosphate group, as
reviewed in [1]. At this stage, the enzyme is particularly vulnerable
to a group of anticancer agents that reversibly trap the complex by
intercalating between DNA base pairs at the cleavage site
(‘‘poisons’’), thereby inhibiting religation [4]. Collision of the
replication machinery with the trapped complex leads to
irreversible DNA strand breaks [5], resulting in activation of
apoptotic and cell cycle arrest pathways [6,7].
The main group of Top1 poisons are derivatives of the alkaloid
camptothecin (CPT, Figure 1) isolated from the bark of the Chinese
tree Camptotheca accuminata [8]. Although camptothecin was found to
be clinically active, further development was hindered due to
problems with solubility and severe side-effects [9,10]. After
identification of Top1 as the target of camptothecin [11], interest
in the development of CPT derivatives as anticancer agents has
increased. Today, two CPT analogues, topotecan and irinotecan
(TTC and CPT-11, Figure 1) are used clinically for the therapy of
both leukaemia and solid tumours [7]. However, their application is
limited due to chemical instability of the hydroxylactone ring,
multidrug-resistance and dose-limiting side-effects [12–14]. Due to
the shortcomings of the camptothecins, there is much interest in the
development of structurally different Top1 inhibitors. Homocamp-
tothecins, containing a 7-membered lactone, and camptothecin
derivatives with a 5-membered ketone ring have been developed to
overcome the instability of the hydroxylactone ring [13,15,16].
Focus has also been put on the development of non-camptothecin
Top1 inhibitors, such as indolocarbazoles, indenoisoquinolines and
phenanthridines [12,17]. Several compounds are currently under
clinical investigation [17].
The use of pharmacophore models is a well-known approach in
computer-aided drug design and its successes in the development
of novel inhibitors have been reported [18]. In the absence of
knowledge of the structure of the target, ligand-based pharmaco-
phore models can be developed using activity data for a pool of
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e25150ligands from an in vitro enzyme inhibition assay [19]. By contrast,
structure-based molecular modelling methods, e.g. structure-based
pharmacophores and docking, are an alternative approach when
structural information about the target protein is available [20].
Here, the availability of several Top1 – DNA – drug crystal
structures [4,21–24] as well as topoisomerase I inhibition data
[25], enabled the identification of structurally novel topoisomerase
I inhibitors using a combination of structure- and ligand-based
molecular modelling techniques. The success of our approach has
been confirmed by the identification of 6 compounds with mild to
moderate Top1 inhibitory activity.
Results
A new pharmacophore feature – cyclic p interaction
A crucial step in the development of high-quality pharmacophore
models is the selection of the appropriate chemical features [26]
enabling the complete description of the interactions between a
ligand and its biological target. Stacking interactions between Top1
inhibitors and the DNA bases at the cleavage site have been reported
to play an important role in the binding of the drug to the Top1 –
DNA cleavable complex [27]. However, the ring aromatic feature
present in DiscoveryStudiosoftware(Accelrys,USA)whichwasused
forthedevelopmentofallpharmacophoremodels(seeMethods),was
observed not to map all rings capable of p-interactions, for example
the DNA base thymine. This led us to the development of a new
pharmacophore feature necessary for this project – the cyclic p-
interaction feature (CYPI). We have designed this feature to map all
five-andsix-memberedringscapableofp-interactionsandhaveused
it in the generation of the following pharmacophores.
Ligand-based Top1 poison pharmacophores
The training set for the ligand-based pharmacophores was
generated from camptothecin derivatives with known IC50 values
measured in a Top1 poison specific assay [28–32]. Camptothecin
derivatives are the only Top1 selective poisons with IC50 data
available from a DNA cleavage assay. From the 77 compounds
that have been tested, 27 were selected as a representative set
(Table S1), chosen because of their structural diversity and activity
spread. 3D QSAR pharmacophore hypotheses were generated as
described in the Methods section. From the 10 hypotheses
generated, two were selected based on statistical analysis. These
two hypotheses show high correlation with biological activity (0.96
and 0.94, respectively) as well as high statistical significance (99%).
The hypotheses also show similarities in the pharmacophore
feature selection and placement (Figure 2). Both models place a
hydrogen bond donor (HBD, pink) feature on the 20-OH group of
camptothecin which is consistent with the importance of the
stereochemistry at this position for compound activity. Further-
more, both pharmacophores contain a cyclic p-interaction (CYPI,
orange) feature at the pyridine ring and a hydrophobic (HYD,
blue) feature at the 20-ethyl group. Nevertheless, the hypotheses
display three important differences – the placement of an HBA
feature on the oxygen of the pyridine-2-one in hypothesis 1, the
placement of a CYPI feature on the pyridine-2-one ring in
hypothesis 2, as well as the placement of excluded volumes (gray).
Thus, given the above characteristics, both pharmacophore
hypotheses were kept for virtual screening.
Structure-based Top1 poison pharmacophore
Structure-based pharmacophore models can be generated when
structural information of protein-ligand complexes is available. In
the case of Top1, several crystal structures of the ternary enzyme-
DNA-drug complex have been published [21–24]. Here, two of
these crystal structures were selected for the development of
structure-based Top1 poison pharmacophores. The selection was
based on the fact that both structures contain similar drug
molecules, camptothecin (PDB code: 1T8I [23]) and topotecan
Figure 1. Chemical structures of camptothecins. Shown are the structures of camptothecin (CPT; top left), topotecan (TTC; top right), and
irinotecan (CPT-11; bottom).
doi:10.1371/journal.pone.0025150.g001
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sequences. The protein-ligand and DNA-ligand interactions in the
selected crystal structures were identified as described in the
Methods section. In general, it was observed that protein-drug
interactions are formed by hydrogen bonds and p-cation
interactions (Figure 3A), whereas the drug contacts with the
DNA are present in the form of p-p-interactions (Figure 3B). The
pharmacophore features were placed according to interactions
common to both crystal structures. The shape of the binding
pocket was taken into account by adding excluded volumes. An
additional excluded volume was placed to enable the distinction
between active and inactive stereoisomers of camptothecin. The
final pharmacophore model (Figure 3C) consists of three CYPI
features, two hydrogen bond acceptors (HBA) and one hydrogen
bond donor (HBD) feature. The positions of the CYPI and HBD
features are similar to those of the ligand-based pharmacophores.
Virtual database screening
The compound database of the National Cancer Institute (NCI,
USA) contains a collection of about 240 000 compounds, many of
which have been tested in vitro for cytotoxicity against human
tumour cell lines. To retrieve novel Top1 inhibitors, and potential
anticancer agents, the Top1 poison pharmacophores were applied
sequentially in virtual screening of the NCI database (Table 1).
Because the software and definition of the CYPI feature do not
allow mapping to fused ring systems that share aromatic bonds,
the two CYPI features of the structure-based pharmacophore
placed on the quinoline rings of camptothecin (Figure 3C) had to
be merged into one feature with a larger location constraint
(Figure 3D), before application in database searching. Screening
with the ligand-based and structure-based pharmacophores
(without excluded volumes) retrieved a hit list of 3474 compounds,
which was further reduced by applying a drug likeness filter based
on Lipinski’s rule of 5 [33]. The resulting list, called generation
1 hit list (see Table 1), consists of 1763 structurally diverse
compounds. 2.7% of the compounds are camptothecin derivatives,
and over half of them (29/46) are ranked within the top 100. As
these compounds were not included in the training set for the
pharmacophore generation, this represents a positive control for
our methodology. Visual inspection of the generation 1 hit list,
however, suggested that many molecules had been retrieved that
might be too large for the binding pocket. Thus, a second
screening was performed using a structure-based pharmacophore
that contained excluded volumes to mimic the shape of the
binding site. This screening reduced the number of hits to 756
compounds (generation 2 hit list, Table 1), 6.3% of which are
Figure 2. Ligand-based pharmacophores for camptothecin derivatives. 2D and 3D representations of the first (A) and second (B)
pharmacophore hypothesis and their mapping to camptothecin. Cyclic p-interaction (CYPI) features are shown in orange, hydrogen bond acceptor
(HBA) features in green, hydrogen bond donor (HBD) features in pink, hydrophobic (HYD) features in blue, and excluded volumes in gray. Mesh
spheres in the 3D representations symbolize location constraints, with the second sphere for CYPI, HBA and HBD features showing the proposed
location of the interacting atoms of the target (protein or DNA). Camptothecin in the 3D representation is shown in colour-coded sticks (carbon: gray,
hydrogen: white, nitrogen: blue, oxygen: red).
doi:10.1371/journal.pone.0025150.g002
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list, however, only a low percentage of the CPT derivatives were
ranked within the top 100 compounds (2 out of 46). 21.8% of the
generation 2 compounds have been tested against human tumour
cell lines (publicly available NCI data), with growth inhibition of
some cell lines reaching GI50 (cell growth inhibition by 50%)
concentrations in the nano-molar range. Both the generation 1
and 2 hit lists were used for the selection of compounds for
biological testing.
Expert selection and molecular docking
The top 20 compounds of the generation 1 and 2 hit lists were
inspected individually for further investigation. This first ‘‘expert
selection’’ method selected according to the following criteria: (1)
the compound is not a camptothecin derivative; (2) it has not been
tested for Top1 inhibition; and (3) it is dissimilar to other
compounds already selected for further investigation. Based on this
method, 22 compounds were chosen and their possible fit into the
Top1-DNA binding pocket was investigated using docking into the
topotecan crystal structure (PDB code: 1K4T [24], see Methods).
As described above, X-ray structures of ternary complexes have
revealed that the binding of known Top1 poisons is stabilised not
only by stacking interactions with the DNA, but also by hydrogen
bondswith the protein.Thus,the bindingsite defined inthedocking
simulations consisted of both DNA and protein residues close to the
DNA cleavage site (Figure S1). All docking settings were tested
beforehand in control dockings of topotecan back into its crystal
structure, and the use of the optimised parameters resulted in
docking poses with a root mean square deviation (RMSD) of 0.91 A ˚
to the ligand position in the crystal structure. In control dockings,
water molecules were found to have no significant effect on the
docking scores and binding pose prediction, and were thus deleted
Figure 3. Structure-based pharmacophore development for camptothecins. (A) Camptothecin in the Top1 active site (from PDB file: 1T8I)
viewed down the DNA helix axis. The protein backbone is shown as a solid ribbon and the protein surface in soft blue. Possible hydrogen bonds and
p-interactions between camptothecin and Top1 are shown in green and orange, respectively (dotted lines), with distances between heavy atoms
shown (A ˚). The amino acids involved are represented as sticks. (B) DNA - camptothecin interactions. DNA shown in green in space-filling mode.
Examples of p-p interactions between camptothecin and flanking DNA bases are indicated in orange (dotted lines). (C) 2D representation of the
structure-based pharmacophore for camptothecins and its mapping to CPT. The pharmacophore is an intersection between the camptothecin and
the topotecan pharmacophores. (D) 3D representation of the pharmacophore used in database screening. Features and camptothecin colours are
represented as in Figure 2.
doi:10.1371/journal.pone.0025150.g003
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short docking run, and an exhaustive run (Figure 4; see Methods
section). If a compound showed satisfactory results in the short
docking, it was passed to the second docking round. The analysis of
docking results was based on the docking scores, as well as on the
poses, the clusters of poses, and the interactions observed between
the ligand and the bindingpocket. In particular, in a second ‘‘expert
selection’’, a docking run was considered satisfactory, if (1) the
docking score was similar to the scores obtained with control
dockings of topotecan, (2) the number of clusters of docking poses
was low, (3) the compound showed an intercalative binding mode
between the DNA bases at the cleavage site, meaning that stacking
interactions were detected and (4) the compound showed hydrogen
bonds to the protein side chains of the binding pocket. In order to
passthefirst(short)dockinground,thefulfilmentofatleast3criteria
was required. This led to the elimination of 6 compounds (Table
S2). In contrast, to pass the second (exhaustive) round of docking,
and therefore to be considered for biological testing, all criteria were
required to be satisfied. Based on this standard, 9 compounds were
selected for biological testing (Table 2 and Figure 5). One additional
compound (NSC 0040666) that showed a high number of docking
clusters, otherwise fulfilled all remaining criteria, and was added to
the test proposal list.
Biological testing of promising compounds
The Top1 DNA cleavage assay is a Top1 poison-specific
method [34,35], which was used to assess the biological function of
the 10 compounds selected from in silico screening. However, out
of 10 compounds only seven were available for testing, with three
and four compounds from the generation 1 and 2 hit lists,
respectively. One particular compound, Scutellaprostin G (NSC
0648335, Figure 5), emerged as the most promising compound of
the virtual screening. This flavonoid isolated from the plant
Scutellaria prostata [36] is highly ranked in both hit lists, receives
high docking scores (similar to topotecan), shows many interac-
tions with the binding site (Figure 6A and D), and displays
promising GI50 values in the low micromolar range (publicly
available NCI data). Unfortunately, Scutellaprostin G was not
available for testing, which prompted us to perform a similarity
search within the NCI database (see Methods section; Tanimoto
similarity [37] .92%), taking into account presence in the hit lists
and satisfactory docking results. However, none of the identified
compounds were available for testing, either. The Top1 inhibitory
activity of the available 7 compounds (Table 2) was assessed semi-
quantitatively, by comparing their activity to the activity of 1 mM
camptothecin (CPT) [34,35]. The results of the assay are shown
in Figure 7 and summarized in Table 3. From the generation 1
compounds, a 2-mercaptobenzenesulphonamide derivative (NSC
674004; rank 16 in generation 1 hit list) shows activity classified
as +/++ (25–75% of CPT activity). In addition, three compounds
of the generation 2 hit list (NSC 0661172, NSC 0318814, and
NSC 0053340; ranks in generation 2 hit list: 15, 17, and 19,
respectively) show + activity (25–50% CPT activity), and one
compound (NSC 0039875, rank 18 in generation 2 hit list) displays
+/++ Top1 inhibitory activity.
As an additional test, the 5 compounds with confirmed
Top1 inhibitory activity have also been tested for cytotoxicity
against the NCI panel of 60 human tumour cell lines (Table 3).
Two of the hit compounds (NSC 0674004 and 0661172), and
camptothecin, had been tested for antitumour activity previously
and the results had been published on-line at the NCI database
website (see Methods). Preliminary testing of the remaining
Table 1. Virtual screening of the NCI database.
National Cancer Institute (NCI, USA) database about 240 000 compounds
Screening with ligand-based pharmacophores 7175 hits
Screening with structure-based pharmacophore (no excluded volumes) 3474 hits
Drug likeness filter 1763 hits
1
Addition of excluded volumes to mimic shape of binding pocket 746 hits
2
1generation 1 hit list,
2generation 2 hit list.
doi:10.1371/journal.pone.0025150.t001
Figure 4. Selection of compounds for biological testing. Overview of the procedure used to select compounds for biological testing. See text
for details.
doi:10.1371/journal.pone.0025150.g004
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activity is expressed as cell growth inhibition (GI50) after 48 h
incubation with the drug. As summarized in Table 3, three of the
tested compounds (NSC 0674004, 0318814, and 0053340) have
GI50 values within the range 15 to 25 mM for some cell lines. The
highest cytotoxic activity was observed in renal cancer (all three
compounds), breast cancer (NSC 0053340 and 0318814), and
non-small cell lung cancer (NSC 0674004) cell lines. The
remaining two compounds (NSC 0661172 and 0039875) show
GI50 values greater than 10 or 100 mM, respectively.
Similarity search within NCI hit lists
Based on the five active compounds identified in the Top1
cleavage assay, we performed another similarity search within the
NCI database (as described above), with the objective of obtaining
compounds with similar structures, but potentially higher activity.
This search led to the identification of five compounds (Figure 5)
present in the virtual screening hit lists, all of which display
satisfactory results in exhaustive docking runs (as described above).
However, only three of these compounds were available for
testing, each being a purine derivative with higher docking
scores, but lower pharmacophore rankings than NSC 0053340. Of
these three compounds, only one, NSC 0042379, shows activity
in the Top1 DNA cleavage assay (Table 3), with a potency and
cytotoxicity similar to NSC 0053340.
Docking poses of most active compounds
The docking poses of the two most active compounds, NSC
0674004 and NSC 0039875, were analysed and compared to the
docking pose of Scutellaprostin G (Figure 6, views down the DNA
axis in A to C, and from the major groove in D). The poses shown
were obtained from exhaustive docking runs. In particular, each
pose represents not only the best-scored pose of the entire docking
run for this ligand, but also the best-scored pose of the biggest
cluster of solutions (clustering: 2.0 A ˚), and can thus be regarded as
a representative putative binding mode. Analysis and superimpo-
sition of the docking poses reveals that the three compounds
intercalate between the DNA base pairs at the cleavage site, each
providing three aromatic rings for extensive base pair stacking,
and form hydrogen bonds to the side chains of the Top1 residues
Arg364 and Lys532. Furthermore, Scutellaprostin G and NSC
0674004 display an additional hydrogen bond to Asp533, and
NSC 0039875 forms a p-cation interaction with Lys425. This
intercalative binding mode, and these Top1 side chain interac-
tions, are common to the camptothecin and topotecan ternary
complexes, and this similarity encourages confidence in the
reliability of the docking.
Discussion
We report the development of ligand- and structure-based
topoisomerase I inhibitor pharmacophore models and their
application in virtual database screening for the identification of
structurally novel inhibitors. To limit the number of hits to be
tested, our methods were extended to include the use of a drug-
likeness filter, molecular docking, and expert selection of
compounds. To our knowledge, this study represents the first use
of combined pharmacophore modelling and docking techniques in
the topoisomerase I poison field. This combination of methods has
enabled us to select 15, and test 10 molecules from the 240,000-
compound National Cancer Institute (NCI) database, 6 of which
show topoisomerase I inhibitory activity. This represents a hit rate
of at least 60%, given that a number of highly rated compounds,
for example Scutellaprostin G, were not available for testing. A
similar hit rate has recently been obtained by Dong and colleagues
[38], who used the crystal structure of the camptothecin-Top1-
DNA complex for docking-based in silico screening of the
commercial SPECS database. These high hit rates compare very
favourably with those of high-throughput screening assays [39],
and highlight the value of computational methods and knowledge-
based selection in the drug development process. Moreover, our
findings support the notion that a combination of ligand- and
structure-based molecular modelling methods, and therefore the
use of all available knowledge, might be the best strategy for a
successful computer-aided drug design [40,41].
Table 2. Compounds that have passed into the second docking round.
List Rank Compound Docking result (docking round 2)
1 3 NSC 0654902 All criteria fulfilled. Proposed for testing, but not available.
1 5 NSC 0648335 All criteria fulfilled. Proposed for testing, but not available.
1 7 NSC 0109617 Few interactions with protein. Not proposed for testing.
1 9 NSC 0614904 All criteria fulfilled. Proposed for testing, but not available.
1 12 NSC 0040666 Many possible binding modes, but other criteria fulfilled. Biol. testing.
1 15 NSC 0674004 All criteria fulfilled. Biol. testing.
1 16 NSC 0270924 All criteria fulfilled. Biol. testing.
1 17 NSC 0149871 Few interactions with protein. Not proposed for testing.
1 18 NSC 0648201 Few interactions with protein. Not proposed for testing.
1 19 NSC 0332448 Either intercal. mode or interactions with protein. Not proposed for testing.
2 13 NSC 0295494 Moderate docking scores. Not proposed for testing.
2 15 NSC 0661172 All criteria fulfilled. Biol. testing.
2 17 NSC 0318814 All criteria fulfilled. Biol. testing.
2 18 NSC 0039875 All criteria fulfilled. Biol. testing.
2 19 NSC 0053340 All criteria fulfilled. Biol. testing.
2 20 NSC 0090917 Low scores. Not proposed for testing.
doi:10.1371/journal.pone.0025150.t002
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cleavage assay are marked with an asterisk (*), if identified through virtual screening (Table 2), and with a cross (+), if identified through a similarity
search.
doi:10.1371/journal.pone.0025150.g005
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compounds with topoisomerase I inhibitory ability, their cytotoxic
potency is only modest, and does not correlate with the Top1
inhibitory activity (see Table 3). As disappointing as it might be,
this is perhaps not surprising. The prediction of cytotoxic
compounds was not the focus of our study, but an additional
test towards the development of new anticancer agents targeting
Top1. Here, we have not attempted to model cytotoxicity, since
cytotoxic activity of a compound is a complex property that
depends on many factors such as drug solubility, cellular uptake,
stability, selectivity, off-target activity, or resistance, which makes
its prediction very difficult. Lipinski’s rule of five was applied
during this study to reduce the number of hits and to focus the hit
list towards potentially orally available drugs. However, it has been
proposed that the chemical space occupied by anticancer drugs is
not a subset of the drug-like compound space, as defined by
Lipinski’s rule, but is of much greater volume [42]. This implies
that in order to focus a compound library towards anticancer
agents, it might be necessary to apply other molecular filters that
have been trained on specific groups of anticancer drugs. To our
knowledge, no such filter has been developed for Top1 inhibitors
yet: an objective that might present an interesting future direction
for use of our pharmacophores.
A noticeable observation during our work was that neither the
ranking after the pharmacophore screening, nor the docking
scores correlate with the actual Top1 inhibitory activity. The
scoring problem is a known challenge in pharmacophore
modelling as well as docking approaches [40]. The ranking of
compounds retrieved by a pharmacophore screening is only based
on a geometrical fit of features and the relative energy of the fitted
conformation, and does not necessarily correlate with the actual
binding affinity or inhibitory activity. Low structural diversity of
the training set during the development of ligand-based pharma-
cophores limits the predictability of the generated pharmaco-
phores. Structure-based pharmacophores, by contrast, do not
include any quantitative information about binding affinities,
which restricts their use to a hit list filtering function. Moreover,
comparative studies have shown that the correlation between
docking scores and in vitro activities is generally low [43] and that
the results are target-dependent [40]. Despite this, the GOLD
program has been shown to perform well in the prediction of
binding poses in protein targets [43]. Since GOLD has not been
validated for docking into DNA, we have tested different settings
and scoring functions in control dockings back into the original
crystal structures, and observed that the GOLD scoring function
gave the best results in terms of RMSD to the original ligand
position. Similar results were obtained by Dong and colleagues
[38] who also tested other docking programs, leading to the
conclusion that GOLD and its scoring function are suitable for this
molecular target. Although the compound ranking according to
the pharmacophore fitting and the docking scores leaves room for
improvement, it is important to emphasize that our selection of
compounds was not only based on these two values, but included a
visual inspection of the docking poses, and that this combined
approach has proven successful, as it resulted in the identification
of active compounds.
Figure 6. Docking results. Interactions between protein side chains and docked ligand: (A) Scutellaprostin G, (B) NSC 0674004, (C) NSC 0039875.
(D) Overlay of docking poses of Scutellaprostin G (gray carbons), NSC 0674004 (pink carbons) and NSC 0039875 (green carbons) within the DNA
cleavage site. See Figure 3 for details of representation and colours.
doi:10.1371/journal.pone.0025150.g006
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activity in human tumour cell lines, our study has identified several
different chemical scaffolds that might be worth further investi-
gation in the Top1 inhibition and anticancer field. One of the
most promising scaffolds derives from 9,10-dioxoanthracene-2-
sulfonic acid, with NSC 0039875 showing comparatively high
Top1 inhibitory ability, albeit little cytotoxicity (Table 3). However,
this does not necessarily imply inactivity of other members of
the chemical family, since one of the hits identified in a structure-
based virtual screening study of Dong et al. [38] has the same
scaffold as NSC 0039875. The hit compound , 4-(p-tolylsulfonyl)-
naphtho-[2,3-g][2,1,3]benzothiadiazole-6,11-dione (38_1), is a Top1
Figure 7. Top1-mediated DNA cleavage induced by tested compounds. (lane 1) DNA alone; (lane 2) Top1 alone; (lane 3) camptothecin,
1 mM; (lane 4) MJ-III-65, 1 mM; (lanes 5–28) Top1 + NCI compounds indicated at 0.1, 1, 10 and 100 mM concentrations, respectively. The numbers on
the left and arrows indicate cleavage site positions.
doi:10.1371/journal.pone.0025150.g007
Table 3. Results of Top1 DNA cleavage assay and cytotoxicity assay.
List Compound CAS-RN
1 Top1 inhibition
2 Cytotoxic activity: GI50
3
1 NSC 0674004 185216-64-2 +/++ Between 15.8 and 100 mM
4
2 NSC 0661172 153621-30-8 + .10 mM for all cells
4
2 NSC 0318814 76867-10-2 + Between 20.0 and .100 mM
5
2 NSC 0053340 93009-81-5 + Between 23.4 and .100 mM
5
2 NSC 0039875 736072-20-1 +/++ .100 mM for all cells
5
Simil. NSC 0042379 92556-40-6 + Between 20.0 and .100 mM
5
Control Camptothecin
(CPT, NSC 0094600)
7689-03-4 ++++ Between 10 nM and 1.3 mM
4
1Chemical Abstracts Registration Number.
2Top1 inhibition ranking: 0 (no activity); + (20–50% of 1 mM CPT activity); ++ (50–75% of 1 mM CPT activity); +++ (75–100% of 1 mM CPT activity); ++++ (equipotent or
more potent than 1 mM CPT).
3Cytotoxic activity measured in the US National Cancer Institute (NCI) 60 human tumour cell line anticancer drug screen [47]. GI50 corresponds to the concentration of
the drug (molar) resulting in a 50% growth inhibition.
4determined previously, published on-line (http://dtp.nci.nih.gov/); in case of camptothecin, the data has been averaged from six experiments, for all other compounds,
only one experiment has been performed.
5determined during this work, data from single experiment.
doi:10.1371/journal.pone.0025150.t003
Discovery of Novel DNA Top1 Poisons
PLoS ONE | www.plosone.org 9 September 2011 | Volume 6 | Issue 9 | e25150inhibitor and shows in vitro antitumour activity in the A-549
non-small-cell lung cancer cell line (IC50=0.5060.0021 mM), as
well as the LOVO (colon cancer, IC50=4361.1 mM) and MDA-
MB-435 (breast cancer, IC50=2560.97 mM) cell lines [38]. The
structural differences between the two compounds include: the
substitution of a toluene group for a hydroxyl group attached to
the sulphur atom of NSC 0039875, the substitution of a thiazole ring
attached to the third ring of the compound for chlorine, and the
presence of an amino substituent in NSC 0039875 (Figure 5). It
should be noted that the binding mode predicted for NSC 0039875
differs from the pose of the structurally related compound 38_1
(see above) regarding the orientation within the binding pocket.
Whereas the sulphate group of NSC 0039875 forms hydrogen bonds
to Lys532 and Thr718 (Figure6C), the sulphate group of 38_1 points
into the opposite direction. In both cases, however, the major axes of
the molecular scaffolds lie parallel to the DNA bases at the cleavage
site. To investigate whether the differences in the binding modes are
due to the use of two distinct crystal structures and slightly different
docking parameters, or whether the differences result from chemical
variations between the compounds, we performed a short control
docking of compound 38_1 using our settings. The best-scored pose
showed a similar orientation to the one described by Dong and
colleagues [38]. When analysing the other poses of the docking run,
however, we found that the largestcluster of poses(RMSD clustering:
2.0 A ˚) showed an orientation similar to the one observed for NSC
0039875, suggesting that both orientations of the scaffold in the
binding pocket are plausible. Irrespective of the binding mode of
these compounds, derivatives of 9,10-dioxoanthracene-2-sulfonic
acid represent an interesting chemical scaffold for systematic QSAR
studies.
Other chemical scaffolds worthy of further investigation include
purine derivatives such as NSC 0053340 and NSC 0042379,
pyrimidine derivatives such as NSC 0318814, and analogues of 2-
mercaptobenzenesulphonamide such as NSC 0674004, which all
display activity in the Top1 inhibition assay and similarly high in
vitro antitumour activity, with the highest potency in renal cancer
cells (GI50 values between 15 and 25 mM, see Table 3). To our
knowledge, none of these compounds have previously been tested
for Top1 inhibition. In addition, although the activity of
Scutellaprostin G has never been tested, we believe that this
molecule and its analogues are a promising group of potential
Top1 inhibitors. This is not only supported by the observations of
good pharmacophore mappings and docking poses for Scutella-
prostins, but also by the fact that Silibinin and other flavonoids
structurally similar to Scutellaprostins have been identified as
DNA intercalators and Top1 poisons [44]. Furthermore, four
Scutellaprostins have been tested for cytotoxicity against the NCI
60 tumour cell line panel (Scutellaprostin A, B, D, and G), with
GI50 concentrations located in the low micromolar range (publicly
available NCI data). A comparison of the docking poses of the
newly identified Top1 inhibitors, and Scutellaprostin G, revealed
that all compounds manifest a similar intercalative binding mode
between the DNA bases at the cleavage site (Figure 6D). Although
comprising different scaffolds, all compounds possess an aromatic
core typical for Top1 inhibitors. Moreover, as shown in Figure 6,
the most active Top1 inhibitors identified in this study, NSC
0674004 and 0039875, as well as Scutellaprostin, display
interactions with Top1 side-chains involved not only in the
binding of camptothecins [21,23,24], but also indenoisoquinolines
and indolocarbazoles [22,23], suggesting a similar mechanism of
action for all compounds.
In conclusion, the combination of pharmacophores, docking
methods and expert assessment can be successfully applied in
virtual database screening to retrieve known Top1 inhibitors,
compounds with anticancer activity, as well as structurally new
compounds with Top1 inhibitory activity. The hit compounds
identified in this study, despite their low cytotoxic activity, can be
regarded as promising starting points for future developments of
anticancer drugs.
Materials and Methods
Ligand-based pharmacophores
Ligand-based pharmacophore models were generated using the
Discovery Studio 2.5.5 package (Accelrys Software Inc. USA). A
training set of 27 camptothecin derivatives was selected from the
literature based on structural and functional diversity [28–32]. All
compounds were sketched manually, their geometry was cleaned
and their conformations were generated using the ‘‘best’’ option.
Pharmacophore models were generated using the HypoGen [45]
and HypoRefine algorithms. Uncertainty values were set to 2.0
and the following pharmacophore features were used: hydrogen
bond acceptor (HBA), hydrogen bond donor (HBD), hydrophobic
(HYD), cyclic p-interaction (CYPI). The CYPI feature is a user-
defined feature that, in contrast to the ring aromatic feature
present in Discovery Studio, maps all five- and six-membered rings
capable of p-interactions. The definition of the feature was based
on the ring aromatic feature present in the software, and extended
by adding all fragments to be mapped. No restrictions were
applied to the number of the pharmacophore features. A
maximum of 5 excluded volumes was allowed. For the validation
of pharmacophore hypotheses, Fischer randomization was used.
Structure-based pharmacophores
Structure-based pharmacophores were developed based on the
crystal structures of ternary DNA topoisomerase I-DNA-drug
complexes. In particular, crystal structures of the drugs campto-
thecin and topotecan were used (PDB codes 1T8I [23] and 1K4T
[24], respectively). Protein-ligand and DNA-ligand interactions
were identified using the Discovery Studio Monitor function and
visual inspection. Pharmacophore features were manually placed
according to identified interactions. For the CYPI feature
placement, the feature mapping protocol was used. A common
pharmacophore was generated containing the features present in
both crystal structures and an average of the features was
calculated. Excluded volumes were placed to mimic the shape of
the binding pocket using a Discovery Studio script. An additional
excluded volume was manually placed to account for the lower
activity of the 20-R stereoisomer (see Figure 1).
Virtual database screening
The compound database of the National Cancer Institute
(NCI2000), imported into Discovery Studio, was screened using
the 3D Database Search protocol in the same software. The
screening was performed sequentially. The hit list was filtered
using Lipinski’s rule of 5 [33].
Docking
All dockings were performed with the program GOLD [46]
version 4.1 and 5.0 using the crystal structure of the topotecan –
Top1 – DNA complex (PDB code: 1K4T). Water molecules and
ligands were deleted, hydrogens were added. The SH-group at the
DNA cleavage site was mutated to OH. The binding site was
defined as the cavity detected 7.5 A ˚ around the initial ligand
position. Flexible side chains were defined according to the
residues observed to interact with the original ligand (Asn352,
Glu356, Arg364, Lys425, Lys532, Asp533, and Thr718). For short
runs, default settings were used. For exhaustive docking runs, the
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population size was increased to 1000, and the number of genetic
algorithm operations was increased to 10
6. Early termination was
allowed if the 5 best poses were within 1.5 A ˚ RMSD (only for
exhaustive runs). The GoldScore function was used to rank the
results. The docking poses were clustered based on 2.0 A ˚ RMSD
of heavy atoms.
DNA cleavage assay
The Top1 inhibitory activity was measured in a DNA cleavage
assay as described previously [25]. Briefly, 39-radiolabeled DNA
substrates are incubated with the Top1 enzyme and the drug to be
tested, allowing the formation of ternary enzyme-DNA-drug
complexes. The use of a strong protein denaturant, sodium
dodecyl sulphate (SDS), leads to a denaturation of Top1 covalently
bound to DNA, and the use of polyacrylamide gel electrophoresis
enables the visualisation of cleavage products. The activity of a
drug is measured semi-quantitatively, by comparison to the
activity of 1 mM camptothecin (CPT). The scoring of the activity
is defined as follows: 0: no activity; +: 25–50% CPT activity; ++:
50–75% CPT activity; +/++: 25–75% CPT activity; +++: 75–
100% CPT activity; ++++: compound is equipotent or more
potent than CPT.
Working with the NCI2000 database
The virtual screening hits were analysed using the NCI2000
database websites (http://129.43.27.140/ncidb2/; http://dtp.nci.
nih.gov/dtpstandard/dwindex/index.jsp). These websites contain
information available for all compounds, including name,
chemical structure, and cancer screening data. They can also be
used to search for compounds based on Tanimoto similarity.
Cytotoxicity assay
The cytotoxicity of selected compounds was measured in the
NCI 60 human tumour cell line anticancer drug screen according
to previously described protocols (see reference [47] and online at
http://dtp.nci.nih.gov/branches/btb/ivclsp.html). Briefly, the
cells were incubated with the drug for 48 h, and stained with
sulforhodamine B. The absorbance was read from an automated
plate reader at a wavelength of 515 nm, and the concentration of
drug needed to inhibit cell growth by 50% recorded as a GI50
value. Except for the control compound camptothecin, the dose-
response curves for the 60 cell lines were obtained from a single
experiment. This was due to the low cytotoxic activity of the
compounds.
Supporting Information
Figure S1 Binding site for the docking simulations. The
binding site was defined from the position of the ligand,
camptothecin, in the crystal structure ternary complex with a
DNA fragment and the top1 enzyme (PDB code 1T8I [23]) and
includes both DNA (green) and protein (aqua) residues.
(TIF)
Table S1 Training set for ligand-based pharmacophore
generation. 2D structures, IC50 values (in mM) for the inhibition
of Top1, and references for molecules used in pharmacophore
generation are given.
(DOCX)
Table S2 Compounds that did not pass the first docking
round. Details on the hit list, the rank, the NSC code are given
on compounds failing the first round of docking, as well as reasons
for failure.
(DOCX)
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